Reference: Kleinman HK & Sosne G (2012)
Some users inject rest days for injury recovery, targeting connective tissue repair rather than hypertrophy
% Daily Value:208333%
Disclosure of interest: Financial support for this study was provided by Alnylam Pharmaceuticals and Biogen Poster Session II - INTRACRANIAL HEMORRHAGE 02.00 - INTRACRANIAL HEMORRHAGE - 02.01 - INTRACEREBRAL HAEMORRHAGE P771 - ESOC25-495 PREHOSPITAL DETECTION OF INTRACRANIAL HEMORRHAGE USING A PORTABLE GFAP DEVICE IN PATIENTS WITH ACUTE FOCAL NEUROLOGICAL DEFICITS OR REDUCED CONSCIOUSNESS TRANSPORTED BY EMERGENCY VEHICLES Iris Voka 1 , Love-Preet Kalra 1 , Sabina Zylyftari 1 , Mastura Ganji 1 , Deepak Bos 1 , Klodiana Meci 1 , Stephan Barthelmes 1 , Gregor Lichy 2,3 , Simon Schwarzach 4 , Till Frscher 5 , Dominik Mayer 5 , Jens Pluto 5 , Timo Breining 5 , Sebastian Luger 1,6 , Christian Foerch 1,6 1 Department of Neurology, RKH Klinikum, Ludwigsburg, Germany, 2 Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, RKH Klinikum, Ludwigsburg, Germany, 3 DRF Luftrettung Stuttgart, Stuttgart, Germany, 4 DRF Luftrettung Karlsruhe, Karlsruhe, Germany, 5 DRK Rettungsdienst Ludwigsburg, Ludwigsburg, Germany, 6 Department of Neurology, University Hospital Frankfurt, Goethe-University, Frankfurt am Main, Germany Background and Aims: Intracerebral hemorrhage(ICH) requires rapid diagnosis for optimal patient outcomes
Safety: Its important to note that while AOD-9604 demonstrated excellent safety and tolerability, the clinical development program was ultimately discontinued because efficacy for weight loss did not meet regulatory approval standards
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
